Wayne CPA - ImmunoCellular Therapeutics CFO Treasurer
| IMUCDelisted Stock | USD 0.47 0.00 0.00% |
Insider
Wayne CPA is CFO Treasurer of ImmunoCellular Therapeutics
| Age | 69 |
| Phone | 201 351 0605 |
| Web | https://www.eompharma.com |
ImmunoCellular Therapeutics Management Efficiency
The company has return on total asset (ROA) of (4.4045) % which means that it has lost $4.4045 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (23.12) %, meaning that it created substantial loss on money invested by shareholders. ImmunoCellular Therapeutics' management efficiency ratios could be used to measure how well ImmunoCellular Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.ImmunoCellular Therapeutics currently holds 2.78 M in liabilities with Debt to Equity (D/E) ratio of 0.39, which is about average as compared to similar companies. ImmunoCellular Therapeutics has a current ratio of 1.48, which is within standard range for the sector. Debt can assist ImmunoCellular Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, ImmunoCellular Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like ImmunoCellular Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for ImmunoCellular to invest in growth at high rates of return. When we think about ImmunoCellular Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Pharming Group NV | 63 | |
| Susanne Embleton | Pharming Group NV | N/A | |
| Ming Yin | Bolt Biotherapeutics | N/A | |
| Steven JD | Longboard Pharmaceuticals | 59 | |
| Brian JD | Catalyst Pharmaceuticals | 60 | |
| Stephen Toor | Pharming Group NV | 52 | |
| Philip Schwartz | Catalyst Pharmaceuticals | 69 | |
| MBA CFA | Bolt Biotherapeutics | 60 | |
| Gary MD | Catalyst Pharmaceuticals | 68 | |
| MD BA | Lumos Pharma | 69 | |
| Shane Lea | Cellectar Biosciences | N/A | |
| Anurag Relan | Pharming Group NV | 51 | |
| Edgar MD | Bolt Biotherapeutics | 78 | |
| Kevin Lind | Longboard Pharmaceuticals | 48 | |
| Megan Knight | Longboard Pharmaceuticals | N/A | |
| Bradley JD | Lumos Pharma | 45 | |
| Ruud Outersterp | Pharming Group NV | 59 | |
| CMA CPA | Catalyst Pharmaceuticals | 51 | |
| Mireille MSc | Pharming Group NV | 55 | |
| Bruce MD | Bolt Biotherapeutics | N/A | |
| Lori CPA | Lumos Pharma | 40 | |
Management Performance
| Return On Equity | -23.12 | ||||
| Return On Asset | -4.4 |
ImmunoCellular Therapeutics Leadership Team
Elected by the shareholders, the ImmunoCellular Therapeutics' board of directors comprises two types of representatives: ImmunoCellular Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImmunoCellular. The board's role is to monitor ImmunoCellular Therapeutics' management team and ensure that shareholders' interests are well served. ImmunoCellular Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImmunoCellular Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Wayne CPA, CFO Treasurer | ||
| Shalom MD, Chief CoFounder | ||
| Eli Goldberger, Chairman Founder | ||
| BS MS, Pres CEO |
ImmunoCellular Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is ImmunoCellular Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -23.12 | ||||
| Return On Asset | -4.4 | ||||
| Current Valuation | (1.69 M) | ||||
| Shares Outstanding | 4.19 M | ||||
| Shares Owned By Insiders | 94.96 % | ||||
| Number Of Shares Shorted | 165.95 K | ||||
| Price To Earning | 0.02 X | ||||
| Price To Book | 0.35 X | ||||
| EBITDA | (6.07 M) | ||||
| Net Income | (5.15 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in ImmunoCellular Pink Sheet
If you are still planning to invest in ImmunoCellular Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoCellular Therapeutics' history and understand the potential risks before investing.
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |